Pharming Group N.V. ADS each representing 10 (PHAR) Peer Comparison

$12.12

$0.22 (1.85%)

As on 27-Oct-2026 10:37EDT

Market cap

$793 Mln

Revenue (TTM)

$366 Mln

P/E Ratio

86.2

P/B Ratio

3

Div. Yield

0 %

Edit

	Pharming Group N.V. ADS each representing 10 (PHAR)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Prime Medicine
Market cap ($ Mln)	793	2,698	2,496	1,595	666
Revenue ($ Mln)	366	450	549	121	4
Net Profit ($ Mln)	9.27	-188.21	17.88	-57.76	-187.89
Net Margin (%)	2.53	-41.86	3.26	-47.60	-4,613.11
RoE (%)	3.39	-28.46	1.43	-9.91	-233.88
Price to Earnings	86.15	--	143.60	--	--
Price-To-Book	2.95	4.56	2.25	3.65	19.54

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Pharming Group N.V. ADS each representing 10 (PHAR)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Prime Medicine
Operating Revenue	366.45	449.61	549.12	120.79	4.07
Cost of Revenue	49.36	195.71	548.01	19.21	47.72
Gross Profit	330.63	269.08	212.72	12.07	-2.69
Operating Expenses	304.74	517.90	35.89	154.86	154.75
Operating Profit (EBIT)	12.35	-264.00	-34.78	-118.11	-196.52
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	15.84	-190.72	20.08	-57.14	-187.89
Provision for Tax	6.57	-2.51	1.66	0.62	0.00
Profit after Tax (Net Income)	9.27	-188.21	17.88	-57.50	-187.89
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Pharming Group N.V. ADS each representing 10 (PHAR)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Prime Medicine
Shareholder's Funds	270.49	607.04	1,260.78	568.41	39.81
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	104.25	39.17	186.25	123.56	177.54
Current Liabilities	93.25	428.58	275.21	81.11	31.69
Total Liabilities	499.81	1,172.38	1,753.10	784.68	342.73

Assets ($ Mln)

	Pharming Group N.V. ADS each representing 10 (PHAR)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Prime Medicine
Non-Current Assets	187.30	160.76	183.02	575.59	152.24
Current Assets	280.69	914.04	1,553.41	197.49	96.80
Total Assets	499.81	1,172.38	1,753.10	784.68	342.73
Total Debt*	113.30	254.58	94.51	127.33	112.48
Net Current Assets	187.44	485.45	0.00	116.38	65.11

Cashflow ($ Mln)

	Pharming Group N.V. ADS each representing 10 (PHAR)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Prime Medicine
Cash From Operating Activities	54.71	-150.79	-64.66	-49.95	-162.56
Cash Flow from Investing Activities	26.25	307.87	-29.41	0.12	-108.76
Cash from Financing Activities	1.50	72.35	7.84	147.34	151.51
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Pharming Group N.V. ADS each representing 10 (PHAR)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Prime Medicine
ROCE (%)	0.77	-18.15	41.92	-15.42	-93.29
ROE (%)	3.39	-28.46	1.43	-10.06	-233.88
ROA (%)	1.69	-12.55	0.66	-6.60	-63.28
EBIT Margin (%)	8.34	-41.09	-6.33	-42.43	-4,613.11
Net Margin (%)	2.53	-41.86	3.26	-47.60	-4,613.11
Cash Profit Margin (%)	0.00	0.00	--	--	0.00

Growth Ratios

	Pharming Group N.V. ADS each representing 10 (PHAR)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Prime Medicine
Revenue Growth (%)	-99.61	5.10	-8.81	602.33	-17.90
EBIT Growth (%)	523.06	11.36	-76.55	17.93	5.71
Net Profit Growth (%)	-99.68	11.44	-96.17	43.71	5.71
EPS Growth (%)	-96.78	-1.87	-96.17	47.43	28.69
Book Value Growth (%)	7.71	-25.05	2.54	-6.65	-52.32

Valuation Ratios

	Pharming Group N.V. ADS each representing 10 (PHAR)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Prime Medicine
Price / Earnings	469.58	-11.11	5.08	-13.58	-2.57
Price / Book Value	4.83	2.73	1.88	2.32	4.27
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	36.65	-9.39	-25.56	-18.38	-2.32
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Pharming Group N.V. ADS each representing 10 (PHAR)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Prime Medicine
Debt to Equity	0.34	0.00	0.00	0.19	0.00
Short term debt to equity ratio	0.03	0.40	0.02	0.02	0.23
Current Ratio	3.01	2.13	5.64	2.43	3.05
Quick Ratio	2.31	1.92	5.50	2.09	3.05
Interest Coverage	2.08	-30.87	-19.05	-4.06	--

Operating Efficiency Ratios

	Pharming Group N.V. ADS each representing 10 (PHAR)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Prime Medicine
Debtors to sales (%)	15.55	16.23	21.41	47.25	0.00
Asset Turnover	0.67	0.30	0.20	0.14	0.01
Receivable days	51.78	77.60	104.79	380.35	--
Inventory Days	492.02	109.55	49.57	791.94	--
Payable days	466.91	231.78	47.68	931.00	504.84
Cash Conversion Cycle	76.89	-44.63	106.67	241.30	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly